BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Omarini C, Guaitoli G, Pipitone S, Moscetti L, Cortesi L, Cascinu S, Piacentini F. Neoadjuvant treatments in triple-negative breast cancer patients: where we are now and where we are going. Cancer Manag Res 2018;10:91-103. [PMID: 29391830 DOI: 10.2147/CMAR.S146658] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Philipovskiy A, Corral J, Dwivedi KA, Heydarian R, Gaur S. Efficacy of Neoadjuvant Versus Adjuvant Chemotherapy in Hispanic/Latino (H/L) Women With Local or Locally Advanced Triple-negative Breast Cancer (TNBC). In Vivo 2019;33:1227-34. [PMID: 31280213 DOI: 10.21873/invivo.11594] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
2 Patwa A, Yamashita R, Long J, Risom T, Angelo M, Keren L, Rubin DL. Multiplexed imaging analysis of the tumor-immune microenvironment reveals predictors of outcome in triple-negative breast cancer. Commun Biol 2021;4:852. [PMID: 34244605 DOI: 10.1038/s42003-021-02361-1] [Reference Citation Analysis]
3 Karpagam S, Mamindla A, Kumar Sali V, Niranjana RS, Periasamy VS, Alshatwi AA, Akbarsha MA, Rajendiran V. Folic acid-conjugated mixed-ligand copper(II) complexes as promising cytotoxic agents for triple-negative breast cancers: A case study using MDA-MB-231 cell. Inorganica Chimica Acta 2022;531:120729. [DOI: 10.1016/j.ica.2021.120729] [Reference Citation Analysis]
4 Liu Y, Xu Z, Zhang Z, Wen G, Sun J, Han F. Efficacy and safety of TE/TEC/intensive paclitaxel neoadjuvant chemotherapy for the treatment of breast cancer. Oncol Lett 2019;17:907-12. [PMID: 30655846 DOI: 10.3892/ol.2018.9658] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Gilmore E, McCabe N, Kennedy RD, Parkes EE. DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy. J Oncol 2019;2019:4325105. [PMID: 31320901 DOI: 10.1155/2019/4325105] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
6 O'Regan RM, Nahta R. Targeting forkhead box M1 transcription factor in breast cancer. Biochem Pharmacol. 2018;154:407-413. [PMID: 29859987 DOI: 10.1016/j.bcp.2018.05.019] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
7 Graeser M, Feuerhake F, Gluz O, Volk V, Hauptmann M, Jozwiak K, Christgen M, Kuemmel S, Grischke EM, Forstbauer H, Braun M, Warm M, Hackmann J, Uleer C, Aktas B, Schumacher C, Kolberg-Liedtke C, Kates R, Wuerstlein R, Nitz U, Kreipe HH, Harbeck N. Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial. J Immunother Cancer 2021;9:e002198. [PMID: 33963012 DOI: 10.1136/jitc-2020-002198] [Reference Citation Analysis]
8 Diaz Casas S, Lancheros García E, Sanchéz Campo A, Sanchez Pedraza R, Roman Vasquez V, Mendoza SD, Angel Aristizabal J, Lehmann Mosquera C, Duarte Torres C, Vergel JC. Clinical Behavior of Triple Negative Breast Cancer in a Cohort of Latin American Women. Cureus 2019;11:e4963. [PMID: 31453035 DOI: 10.7759/cureus.4963] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
9 Abdollahzadeh F, Nejatollahi F. Anti-Proliferative Effect of Specific Anti-EGFR Single Chain Antibody on Triple Negative Breast Cancer Cells. Rep Biochem Mol Biol 2020;9:180-7. [PMID: 33178867 DOI: 10.29252/rbmb.9.2.180] [Reference Citation Analysis]
10 El Guerrab A, Bamdad M, Bignon YJ, Penault-Llorca F, Aubel C. Co-targeting EGFR and mTOR with gefitinib and everolimus in triple-negative breast cancer cells. Sci Rep 2020;10:6367. [PMID: 32286420 DOI: 10.1038/s41598-020-63310-2] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 6.5] [Reference Citation Analysis]
11 Lothstein L, Soberman J, Parke D, Gandhi J, Sweatman T, Seagroves T. Pivarubicin Is More Effective Than Doxorubicin Against Triple-Negative Breast Cancer In Vivo. Oncol Res 2020;28:451-65. [PMID: 32430093 DOI: 10.3727/096504020X15898794315356] [Reference Citation Analysis]
12 Cheng SW, Chen PC, Ger TR, Chiu HW, Lin YF. GBP5 Serves as a Potential Marker to Predict a Favorable Response in Triple-Negative Breast Cancer Patients Receiving a Taxane-Based Chemotherapy. J Pers Med 2021;11:197. [PMID: 33809079 DOI: 10.3390/jpm11030197] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
13 Nadesh R, Menon KN, Biswas L, Mony U, Subramania Iyer K, Vijayaraghavan S, Nambiar A, Nair S. Adipose derived mesenchymal stem cell secretome formulation as a biotherapeutic to inhibit growth of drug resistant triple negative breast cancer. Sci Rep 2021;11:23435. [PMID: 34873206 DOI: 10.1038/s41598-021-01878-z] [Reference Citation Analysis]
14 Zwartsen A, Chottanapund S, Kittakoop P, Navasumrit P, Ruchirawat M, Van Duursen MBM, Van den Berg M. Evaluation of anti-tumour properties of two depsidones - Unguinol and Aspergillusidone D - in triple-negative MDA-MB-231 breast tumour cells. Toxicol Rep 2019;6:1216-22. [PMID: 31788435 DOI: 10.1016/j.toxrep.2019.10.012] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
15 Korolkova OY, Widatalla SE, Whalen DS, Nangami GN, Abimbola A, Williams SD, Beasley HK, Reisenbichler E, Washington MK, Ochieng J, Mayer IA, Lehmann BD, Sakwe AM. Reciprocal expression of Annexin A6 and RasGRF2 discriminates rapidly growing from invasive triple negative breast cancer subsets. PLoS One 2020;15:e0231711. [PMID: 32298357 DOI: 10.1371/journal.pone.0231711] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
16 Zheng BH, He ZX, Zhang J, Ma JJ, Zhang HW, Zhu W, Shao ZM, Ni XJ. The Biological Function of TUSC7/miR-1224-3p Axis in Triple-Negative Breast Cancer. Cancer Manag Res 2021;13:5763-74. [PMID: 34305410 DOI: 10.2147/CMAR.S305865] [Reference Citation Analysis]
17 Escrivá-de-Romaní S, Arumí M, Zamora E, Bellet M. Neoadjuvant Model as a Platform for Research in Breast Cancer and Novel Targets under Development in this Field. Breast Care (Basel) 2018;13:251-62. [PMID: 30319327 DOI: 10.1159/000492122] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
18 Liu W, Xiong X, Chen W, Li X, Hua X, Liu Z, Zhang Z. High expression of FUSE binding protein 1 in breast cancer stimulates cell proliferation and diminishes drug sensitivity. Int J Oncol 2020;57:488-99. [PMID: 32626933 DOI: 10.3892/ijo.2020.5080] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Vougiouklakis T, Saloura V, Park JH, Takamatsu N, Miyamoto T, Nakamura Y, Matsuo Y. Development of novel SUV39H2 inhibitors that exhibit growth suppressive effects in mouse xenograft models and regulate the phosphorylation of H2AX. Oncotarget 2018;9:31820-31. [PMID: 30159125 DOI: 10.18632/oncotarget.25806] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
20 Hill DP, Harper A, Malcolm J, McAndrews MS, Mockus SM, Patterson SE, Reynolds T, Baker EJ, Bult CJ, Chesler EJ, Blake JA. Cisplatin-resistant triple-negative breast cancer subtypes: multiple mechanisms of resistance. BMC Cancer. 2019;19:1039. [PMID: 31684899 DOI: 10.1186/s12885-019-6278-9] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
21 Miodragović Ð, Qiang W, Sattar Waxali Z, Vitnik Ž, Vitnik V, Yang Y, Farrell A, Martin M, Ren J, O'Halloran TV. Iodide Analogs of Arsenoplatins-Potential Drug Candidates for Triple Negative Breast Cancers. Molecules 2021;26:5421. [PMID: 34500854 DOI: 10.3390/molecules26175421] [Reference Citation Analysis]
22 Reddy TP, Choi DS, Anselme AC, Qian W, Chen W, Lantto J, Horak ID, Kragh M, Chang JC, Rosato RR. Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs. Breast Cancer Res 2020;22:48. [PMID: 32414394 DOI: 10.1186/s13058-020-01280-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
23 Hu MH, Wu TY, Huang Q, Jin G. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription. Nucleic Acids Res 2019;47:10529-42. [PMID: 31584090 DOI: 10.1093/nar/gkz835] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 14.5] [Reference Citation Analysis]
24 da Silva JL, de Paula BHR, Small IA, Thuler LCS, de Melo AC. Sociodemographic, Clinical, and Pathological Factors Influencing Outcomes in Locally Advanced Triple Negative Breast Cancer: A Brazilian Cohort. Breast Cancer (Auckl) 2020;14:1178223420962488. [PMID: 33029072 DOI: 10.1177/1178223420962488] [Reference Citation Analysis]
25 Przybytkowski E, Davis T, Hosny A, Eismann J, Matulonis UA, Wulf GM, Nabavi S. An immune-centric exploration of BRCA1 and BRCA2 germline mutation related breast and ovarian cancers. BMC Cancer 2020;20:197. [PMID: 32164626 DOI: 10.1186/s12885-020-6605-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 4.0] [Reference Citation Analysis]
26 Piña-Sánchez P, Valdez-Salazar HA, Ruiz-Tachiquín ME. Circulating microRNAs and their role in the immune response in triple-negative breast cancer. Oncol Lett 2020;20:224. [PMID: 32968446 DOI: 10.3892/ol.2020.12087] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
27 Dieci MV, Del Mastro L, Cinquini M, Montemurro F, Biganzoli L, Cortesi L, Zambelli A, Criscitiello C, Levaggi A, Conte B, Calabrese M, Fiorentino A, Marchiò C, Tinterri C, Fittipaldo VA, Pappagallo G, Gori S. Inclusion of Platinum Agents in Neoadjuvant Chemotherapy Regimens for Triple-Negative Breast Cancer Patients: Development of GRADE (Grades of Recommendation, Assessment, Development and Evaluation) Recommendation by the Italian Association of Medical Oncology (AIOM). Cancers (Basel) 2019;11:E1137. [PMID: 31398896 DOI: 10.3390/cancers11081137] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Blenman KRM, He TF, Frankel PH, Ruel NH, Schwartz EJ, Krag DN, Tan LK, Yim JH, Mortimer JE, Yuan Y, Lee PP. Sentinel lymph node B cells can predict disease-free survival in breast cancer patients. NPJ Breast Cancer 2018;4:28. [PMID: 30155518 DOI: 10.1038/s41523-018-0081-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
29 Ogbu SC, Rojas S, Weaver J, Musich PR, Zhang J, Yao ZQ, Jiang Y. DSTYK Enhances Chemoresistance in Triple-Negative Breast Cancer Cells. Cells 2021;11:97. [PMID: 35011659 DOI: 10.3390/cells11010097] [Reference Citation Analysis]
30 Gao B, Liu X, Li Z, Zhao L, Pan Y. Overexpression of EZH2/NSD2 Histone Methyltransferase Axis Predicts Poor Prognosis and Accelerates Tumor Progression in Triple-Negative Breast Cancer. Front Oncol 2020;10:600514. [PMID: 33665162 DOI: 10.3389/fonc.2020.600514] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Dittmer A, Lange T, Leyh B, Dittmer J. Protein‑ and growth‑modulatory effects of carcinoma‑associated fibroblasts on breast cancer cells: Role of interleukin‑6. Int J Oncol 2020;56:258-72. [PMID: 31789400 DOI: 10.3892/ijo.2019.4918] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
32 Dittmer A, Dittmer J. Carcinoma-Associated Fibroblasts Promote Growth of Sox2-Expressing Breast Cancer Cells. Cancers (Basel) 2020;12:E3435. [PMID: 33228022 DOI: 10.3390/cancers12113435] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]